Notably, FLT3 and NPM1, common driver variants associated with the development of myeloid leukemia, are virtually non-existent in CH, suggesting that the acquisition of these variants likely occurs later in the pathogenesis of AML and is strongly linked to leukemogenesis (Desai et al., 2018; McKerrell et al., 2015). This evidence concerns the gene FLT3 and cyclic hematopoiesis.